Invivyd Gets FDA Emergency Use Approval to Prevent Covid-19 in Immunocompromised Adolescents, Adults
By Sabela Ojea
Invivyd said the U.S. Food and Drug Administration granted emergency use authorization to its Pemgarda monoclonal antibody to prevent Covid-19 in immunocompromised adolescents and adults.
The biotechnology company on Friday said that the authorization of Pemgarda, administered as an intravenous infusion, targets people aged at least 12 weighing at least 40 kilograms, or about 88 pounds.
Recipients shouldn't be infected with the Covid or have had a recent exposure to an individual infected with the virus ahead of the intravenous infusion, Invivyd said.
The company said people who are immunocompromised continue to be disproportionally affected by Covid, even after receiving multiple vaccine doses.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
March 22, 2024 15:41 ET (19:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing